🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for HER2+ Metastatic Breast Cancer

Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor NCT05933395Phase 21 site📍 Lebanon Dartmouth-Hitchcock Medical Center · Tests: Fulvestrant, Neratinib, Alpelisib, Everolimus, Abemaciclib Elacestrant in Patients With ER+ HER2- ESR1-mutated Locally Advanced or Metastatic Breast Cancer NCT07563595n/a3 sites📍 Freiburg im Breisgau📍 Paderborn📍 Ravensburg iOMEDICO AG · Tests: Elacestrant, Standard of care (Investigator Choice) Study Evaluating DNA Double-strand Breaks (DSBs) REpair Factors (POLQ, Shieldin Complex and 53BP1) Expression as Biomarker of PARP Inhibitor Resistance in Patients With Deleterious Germline Mutation in BRCA 1/2 and HER2-negative, Metastatic or Locally Advanced Breast Cancer. NCT05378204NA25 sites📍 Bordeaux📍 Caen📍 Clermont-Ferrand Institut Claudius Regaud · Tests: Main study:, Sub-study: Utidelone Versus Docetaxel in HER2-negative Locally Advanced or Metastatic Breast Cancer NCT05430399Phase 32 sites📍 Guangzhou📍 Hunan Sun Yat-sen University · Tests: utidelone, docetaxel Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer NCT04090567Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Cediranib, Ceralasertib, Olaparib Step Count and Treatment Response in Neoadjuvant Breast Cancer NCT07162675n/a2 sites📍 Ankara📍 Ankara Ankara Etlik City Hospital · Tests: Huawei Fit 2 Smartwatch Efficacy of Trastuzumab Deruxtecan in Metastatic Breast Cancer With Different HER2 Expression Patterns NCT06551220n/a26 sites📍 New Haven📍 Boston📍 Fuzhou Sun Yat-sen University · Tests: Trastuzumab Deruxtecan A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer NCT06678269Phase 17 sites📍 Basking Ridge📍 Middletown📍 Montvale Memorial Sloan Kettering Cancer Center · Tests: Abemaciclib, Radiation Therapy A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors NCT07318805Phase 113 sites📍 Duarte📍 Grand Rapids📍 Long Island City Pfizer · Tests: PF-08032562, Fulvestrant, Cetuximab, Fluorouracil, Oxaliplatin Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer NCT06179303Phase 23 sites📍 St Louis📍 Chapel Hill📍 Seattle University of Washington · Tests: Abemaciclib, Anastrozole, Biospecimen Collection, Computed Tomography, Diagnostic Imaging Testing DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs NCT06176261Phase 23 sites📍 Miami📍 Boston📍 Durham Nancy Lin, MD · Tests: Datopotamab Deruxtecan Analysis of Circulating Tumor DNA (ctDNA) in HER2-low Advanced/Metastatic Breast Cancer NCT06706557n/a1 site📍 Milan European Institute of Oncology A Study Comparing BL-M07D1 With DS-8201 in Patients With HR-Positive, HER2-Low Expressing Recurrent/Metastatic Breast Cancer NCT07678957Phase 21 site📍 Beijing Sichuan Baili Pharmaceutical Co., Ltd. · Tests: BL-M07D1, DS-8201 Asciminib in HER2+ Breast Cancer Brain Metastases NCT07136428Phase 1, Phase 21 site📍 Durham Duke University · Tests: Asciminib and Trastuzumab Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer NCT05950945Phase 388 sites📍 Miami Beach📍 Tampa📍 Boston Daiichi Sankyo · Tests: Trastuzumab Deruxtecan HR+/HER2- Advanced or Metastatic Breast Cancer Patients Treated With Sacituzumab Govitecan NCT06236269Phase 210 sites📍 Badalona📍 L'Hospitalet de Llobregat📍 Barcelona SOLTI Breast Cancer Research Group · Tests: Sacituzumab Govitecan A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer NCT07347600n/a32 sites📍 Xiamen📍 Lanzhou📍 Shijiazhuang Hoffmann-La Roche · Tests: Inavolisib, Palbociclib, Fulvestrant A Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy NCT07071337Phase 32 sites📍 Beijing📍 Guangzhou Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · Tests: SKB264, Nab-paclitaxel, Paclitaxel, Capecitabine Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer NCT05524584Phase 21 site📍 Orange University of California, Irvine · Tests: Fulvestrant, Anastrozole, Abemaciclib HER2+ CNS Surveillance NCT07748598NA1 site📍 Liverpool The Clatterbridge Cancer Centre NHS Foundation Trust · Tests: Intervention for Arm 2: Brain MRI Surveillance A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+/HER2- Breast Cancer After Failure of Prior Endocrine Therapy(PANKU-Breast03) NCT07648914Phase 31 site📍 Beijing Sichuan Baili Pharmaceutical Co., Ltd. · Tests: BL-B01D1, Albumin-Bound Paclitaxel, Paclitaxel, Capecitabine Clinical Trial of Avasopasem in Patients With Metastatic Hormone Receptor Positive Breast Cancer With Progression on a CDK 4/6 Inhibitor and Hormonal Therapy NCT07137871Phase 11 site📍 San Antonio The University of Texas Health Science Center at San Antonio · Tests: Avasopasem HER2 Targeted Molecular Imaging in mBC and Other Metastatic Solid Carcinomas Using 68Ga-ABS011 NCT06369831Phase 27 sites📍 Innsbruck📍 Brussels📍 Brussels Abscint NV/SA · Tests: 68Ga-NOTA-ABSCINT-HER2 PET/CT Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors NCT07288359Phase 1, Phase 216 sites📍 Atlanta📍 Nashville📍 San Antonio Novartis Pharmaceuticals · Tests: GVV858, Fulvestrant, Letrozole A Study to Explore Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Novel Therapeutics in Patients With Early Relapsed Metastatic Triple-negative Breast Cancer NCT06508216Phase 1, Phase 21 site📍 Villejuif Gustave Roussy, Cancer Campus, Grand Paris · Tests: Dato-DXd, Durvalumab Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial NCT06278870Phase 31 site📍 Guangzhou Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Tests: disitamab vedotin, Pyrotinib, trastuzumab, Pertuzumab, taxane drug Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors NCT05969041Phase 16 sites📍 Darlinghurst📍 Randwick📍 Westmead Myeloid Therapeutics · Tests: MT-302 (A) Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC) NCT05660083Phase 23 sites📍 Bethesda📍 Houston📍 Houston The Methodist Hospital Research Institute · Tests: L-NMMA DESTINY Breast Respond HER2-(Ultra)Low Europe NCT05945732n/a216 sites📍 Graz📍 Graz📍 Innsbruck Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company · Tests: Trastuzumab deruxtecan ECLECTIC: EstroTEP and Circulating Biomarkers for ER-positive HER2-negative Metastatic Breast Cancer Patients NCT06195709Phase 321 sites📍 Bayonne📍 Bordeaux📍 Bordeaux Institut Curie · Tests: Endocrine therapy, Endocrine therapy combined with the local treatment of FES-negative lesions, Chemotherapy
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy